MA26430A1 - 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26430A1
MA26430A1 MA24613A MA24613A MA26430A1 MA 26430 A1 MA26430 A1 MA 26430A1 MA 24613 A MA24613 A MA 24613A MA 24613 A MA24613 A MA 24613A MA 26430 A1 MA26430 A1 MA 26430A1
Authority
MA
Morocco
Prior art keywords
quinazolinones
disubstituted
novel
preparation
pharmaceutical compositions
Prior art date
Application number
MA24613A
Other languages
English (en)
Inventor
M Welch Willard Jr
L Elliott Mark
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26430A1 publication Critical patent/MA26430A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
MA24613A 1996-05-15 1997-05-14 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant MA26430A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
MA26430A1 true MA26430A1 (fr) 2004-12-20

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24613A MA26430A1 (fr) 1996-05-15 1997-05-14 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (39)

Country Link
US (1) US6303615B1 (fr)
EP (1) EP0901487B9 (fr)
JP (1) JP3241388B2 (fr)
KR (1) KR100375155B1 (fr)
CN (2) CN1103772C (fr)
AP (1) AP1148A (fr)
AR (1) AR007118A1 (fr)
AT (1) ATE242232T1 (fr)
AU (1) AU730503B2 (fr)
BG (1) BG102999A (fr)
BR (1) BR9709085A (fr)
CA (1) CA2252907C (fr)
CZ (1) CZ295565B6 (fr)
DE (1) DE69722613T2 (fr)
DK (1) DK0901487T3 (fr)
DZ (1) DZ2237A1 (fr)
EA (1) EA002905B1 (fr)
ES (1) ES2198546T3 (fr)
GT (1) GT199700049A (fr)
HK (1) HK1019607A1 (fr)
HN (1) HN1997000052A (fr)
HR (1) HRP970261B1 (fr)
HU (1) HUP9902148A3 (fr)
ID (1) ID17149A (fr)
IL (1) IL126589A (fr)
IS (1) IS4881A (fr)
MA (1) MA26430A1 (fr)
NO (1) NO985293L (fr)
OA (1) OA10918A (fr)
PL (1) PL330042A1 (fr)
PT (1) PT901487E (fr)
SI (1) SI0901487T1 (fr)
SK (1) SK284108B6 (fr)
TN (1) TNSN97087A1 (fr)
TR (1) TR199802296T2 (fr)
TW (1) TW539675B (fr)
WO (1) WO1997043276A1 (fr)
YU (1) YU19197A (fr)
ZA (1) ZA974156B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK113299A3 (en) * 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
NZ336627A (en) * 1997-02-28 2000-12-22 Pfizer Prod Inc Atropisomers of 3-heteroaryl-4(3)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
DE60027546T2 (de) * 1999-02-15 2007-04-26 Eisai Co., Ltd. Heterodiazinon-derivate
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
KR100850728B1 (ko) 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도
US7053216B2 (en) * 2001-11-19 2006-05-30 Iconix Pharmaceuticals, Inc. Modulators of Rho C activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1537089A4 (fr) * 2002-07-23 2008-04-16 Cytokinetics Inc Composes, compositions et procedes
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
TWI409070B (zh) * 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
WO2008140750A1 (fr) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Composés modulant la fonction du trp v3
MY157495A (en) * 2007-09-26 2016-06-15 Celgene Corp 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US8404696B2 (en) 2008-01-30 2013-03-26 Shin Poong Pharmaceutical Co., Ltd. Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
WO2010111432A1 (fr) 2009-03-24 2010-09-30 Calistoga Pharmaceuticals Inc. Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation
EA201101507A1 (ru) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
KR20140133590A (ko) 2012-03-05 2014-11-19 길리아드 칼리스토가 엘엘씨 (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
CA2934531C (fr) 2013-12-20 2020-02-25 Gilead Calistoga Llc Procedes de synthese d'inhibiteurs de la phosphatidylinositol 3-kinase
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
EP3893844A1 (fr) 2018-12-14 2021-10-20 Eisai R&D Management Co., Ltd. Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
AU2021212754A1 (en) 2020-01-29 2022-08-04 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
GB1298603A (en) 1970-04-06 1972-12-06 Karamchand Premchand Private Quinazolinone derivatives
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1994026746A1 (fr) 1993-05-06 1994-11-24 Novo Nordisk A/S COMPOSES A BASE DE [1,2,4]TRIAZOLO[4,3-a]QUINOXALINE, LEUR PREPARATION ET LEUR EMPLOI
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists

Also Published As

Publication number Publication date
CA2252907C (fr) 2005-05-17
JP3241388B2 (ja) 2001-12-25
AP1148A (en) 2003-02-28
EA199800923A1 (ru) 1999-06-24
TR199802296T2 (xx) 1999-02-22
DE69722613D1 (de) 2003-07-10
CZ295565B6 (cs) 2005-08-17
HUP9902148A2 (hu) 2000-04-28
NO985293D0 (no) 1998-11-13
CN1218464A (zh) 1999-06-02
HN1997000052A (es) 1997-06-26
GT199700049A (es) 1998-10-21
PT901487E (pt) 2003-08-29
SI0901487T1 (en) 2003-10-31
TW539675B (en) 2003-07-01
DZ2237A1 (fr) 2002-12-03
TNSN97087A1 (fr) 2005-03-15
SK152098A3 (en) 2000-05-16
YU19197A (sh) 1999-09-27
CN1103772C (zh) 2003-03-26
PL330042A1 (en) 1999-04-26
NO985293L (no) 1999-01-13
DK0901487T3 (da) 2003-08-25
EA002905B1 (ru) 2002-10-31
HK1019607A1 (en) 2000-02-18
WO1997043276A1 (fr) 1997-11-20
US6303615B1 (en) 2001-10-16
HRP970261A2 (en) 2000-12-31
HRP970261B1 (en) 2003-06-30
ES2198546T3 (es) 2004-02-01
ZA974156B (en) 1998-11-16
BG102999A (en) 1999-09-30
AP9701003A0 (en) 1997-07-31
IL126589A0 (en) 1999-08-17
IS4881A (is) 1998-10-27
IL126589A (en) 2003-06-24
CN1420114A (zh) 2003-05-28
KR20000011054A (ko) 2000-02-25
KR100375155B1 (ko) 2003-08-19
OA10918A (en) 2001-10-25
EP0901487A1 (fr) 1999-03-17
CA2252907A1 (fr) 1997-11-20
ATE242232T1 (de) 2003-06-15
BR9709085A (pt) 1999-08-03
JPH11514663A (ja) 1999-12-14
ID17149A (id) 1997-12-04
AU730503B2 (en) 2001-03-08
AU1554997A (en) 1997-12-05
HUP9902148A3 (en) 2002-11-28
EP0901487B9 (fr) 2004-09-29
EP0901487B1 (fr) 2003-06-04
SK284108B6 (sk) 2004-09-08
CZ352698A3 (cs) 1999-11-17
AR007118A1 (es) 1999-10-13
DE69722613T2 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
MA26438A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26451A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA23831A1 (fr) Derives de quinazoline, procede pour leur preparation et composition les contenant
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
MA23866A1 (fr) N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.